ARTOI
Integrative Oncology Therapy Research Association
New Article on nutrition
Article on nutrition
March 26, 2012: Published in the ARTOI site a new article by Prof. Massimo Bonucci on the theme of nutrition.
New article on Traditional Chinese Medicine
26/03/2012. We publish a new article by Prof. Massimo Bonucci on Traditional Chinese Medicine.
Online the ARTOI’s YouTube channel: ARTOI TV
30/01/2012 It’s now online our new YouTube channel.
The first video we uploaded is a recent interview to Professor Massimo Bonucci, during the third International Congress of integrative oncology therapy.
Please, subscribe to the channel, share and like it!
The technical staff of ARTOI.IT
The video of the III International Congress of Integrative Oncology
We publish the first video about the congress held in Rome on 2, 3 december 2011.
8th International Conference of the Society for Integrative Oncology
It is concluded in Cleveland the Eighth Conference of the SIO (Society for Integrative Oncology). We publish a summary by Dr. Massimo Bonucci:The complete overview on the treatment of cancer has been the subject of extensive study during all three days of the 8th International Conference of the American Society for Integrative Oncology, held in Cleveland (Ohio, USA). The American Society for Integrative Oncology was founded about 10 years ago for the will of oncology colleagues, researchers and medical specialists who wanted to meet and discuss to find new solutions for the welfare of cancer patients.In this conference with the title “Innovating Integrative Oncology: New Science, New solution. The focus is the Patient” were addressed all the problems of cancer therapy and evaluated all the opportunities to improve the results.
An “open” vision of treatment, which has touched all areas: chemotherapy, radiotherapy, immunotherapy, phytotherapy, mind-body therapy, acupuncture.
One of the focuses of the conference was to assess the integration of natural substances with chemotherapy and radiotherapy. One concerned the “oxidative stress and cancer” and how antioxidants can or not interfere with the chemo and radiation. These reports were taken by Prof. Aggarwal of the MD Anderson Cancer Center in Houston. His data have helped to clarify how many natural substances and many antioxidants compounds (vitamins and minerals are an example) lead to an improvement in the quality of life as well as an adjuvant synergistic effect in combination with chemotherapy and radiotherapy. Curcumin and resveratrol are now considered molecules able to interact positively in combination with chemotherapy for various solid tumors (lung, breast, colon).
It was held discussion on clinical evidence of case studies of integrative cancer therapy and particularly appreciated the work done by Dr. Bonucci and his colleagues, Dr. Pastore and Dr. Ferrera on cases of peritoneal carcinomatosis from ovarian cancer.
Another focus was acupuncture, with its effectiveness in preventing and reducing several side effects of chemotherapy and radiotherapy.
Then, great interest has been given to therapy “mind-body” with all the psychosocial aspects but also its influence on the results as a possible “epigenetic” intervention on the tumor itself.
The hope is that all these innovations and scientific opportunities may become the heritage of all, doctors and patients, so we may give a greater knowledge and awareness to those who face, although in different locations, the neoplastic disease.
Interview with Dr. Bonucci on Telegenova
We publish the entire interview with Dr. Bonucci on Telegenova, September 26, 2011, lasting about 25 minutes.
Enjoy it.
The use of metformin as an adjuvant in integrative cancer treatment
Metformin is a hypoglycaemic drug that is used in conditions of hyperglycemia.
Besides its function to reduce the level of circulating sugars, it has been recently investigated and used as an agent able to interfere positively with the homeostasis and cell growth and as an agent suitable for the prevention of some cell changes that exist in cancer.
Metformin, in addition to some activity of modulation of the immune system and hormonal and body buoyancy, has shown even a blocking action of cell growth and a protective effect on vascular endothelium. Studies in basic research and also translated into therapeutic applications, have shown its primary action as a reducing agent of the neoplastic cell proliferative effect of insulin.
Further studies are underway to test its use as an adjuvant agent in cancer conditions and as a therapeutic agent to accompany any antiblastic chemotherapy or radiotherapy and hyperthermia.
Following one of the most important studies on the use of metformin.
J Diabetes. 2011 Feb 21. doi: 10.1111/j.1753-0407.2011.00119.x. [Epub ahead of print]
Metformin as an Antitumor Agent in Cancer Prevention and Treatment.
Li D.
Source: Department of Gastrointestinal Medical Oncology, The University of Texas MD
Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
Abstract:
Recent epidemiological investigations conducted in diabetic cohorts and cancer
patients have found that metformin users have lower risks for cancer than
insulin or insulin secretogogue users. Studies conducted in various animal
tumor models and cancer cell lines have demonstrated that metformin prevents
tumor development or inhibits cell proliferation. In addition, a recent
clinical trial has shown that short-term use of metformin reduced aberrant
crypt foci (ACF) formation in nondiabetic patients with ACF. The antitumor
activity of metformin could be mediated through its regulatory effect on
hormonal, metabolic, and immune functions. Metformin achieves glycemic control
by reducing hepatic glucose production and increasing the muscle intake of
glucose, thus lowering levels of circulating glucose and, consequently, of
insulin. The major molecular targets of metformin are the liver kinase B1 (LKB1)
-5′AMP-activated protein kinase (AMPK) signaling and mTOR pathways, which are
central to the regulation of cellular energy homeostasis and play a crucial
role in the control of cell division and cell proliferation. Metformin has been
shown to improve endothelial function, decrease inflammatory activity, and
regulate immune function. Increasing experimental evidence provides a strong
biological rationale for metformin as an antitumor and chemopreventive agent.
Metformin is being tested as an adjuvant cancer therapy in clinical settings,
and use of metformin is recommended for all cases of type 2 diabetes without
contraindications. As we show in the current review, the chemopreventive value
of this drug is not restricted to diabetic or obese individuals.
Copyright © 2011 Ruijin Hospital and Blackwell Publishing Asia Pty Ltd.
Online the new website ARTOI
Rome, August 28, 2011
It is now online the new website of A.R.T.O.I.. It is possible that in these early stages you may encounter technical problems for which we apologize right now.
Please report any bug to: webmaster@artoi.it
Thanks and enjoy reading,
The technical staff of A.R.T.O.I.
Chemotherapy and Phytotherapy
A new contribution to the combined and integrative use of chemotherapy and phytotherapy comes from this article that revisits the American studies of mistletoe (Viscum album) and cùyclophosphamide or gemcitabine in case of solid tumors.
Avastin (Roche) rejected by FDA
The FDA has announced that from the data obtained, serious side effects and poor results, the use of Avastin in breast cancer cases has not been approved. The pharmaceutical company Roche reiterated its willingness to do further study, however.
L’ipertermia fa progressi in Texas
La notizia che viene riportata è molto importante, perché conferma quanto viene detto nel campo della integrazione oncologica molto tempo nei riguardi della Ipertermia: è una valida metodologia contro le neoplasie.
I colleghi del Texas Oncology, affiliati all’U.S. Oncology hanno acquistato le macchine per la Ipertermia capacitativa profonda, procedendo a sviluppare protocolli di trattamento oncologico.
First International conference on integrative care for the future
Amsterdam March, 11-12 2011
Conference Chair Barrie Cassileth, PhD – Conference Organizer Mischa P.M. Nagel More Info
Nov. 2010: “Incontri con la Scienza”
Sono aperte le iscrizioni per il Meeting del 20/11/2010 Università “G.Marconi” di Roma locandina
Article first published online: 16 Sep 2009
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors more info
2010 February – Int J Hyperthermia. 2010 Feb;26(1):21-5
Chemoradiation with hyperthermia in the treatment of… (Huilgol NG, Gupta S, Dixit R.) more info
Nature. 2009, 457: 910-915
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression more info
Integrated Cancer Therapy 2009 Dec;8(4):337-46
Molecular mechanisms of… (Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, Mao L.) more info
2009 December – Cancer Therapy Vol 7, 397-401, 2009
Biotherapy with the pineal hormone melatonin plus aloe and myrrh tincture in untreatable… more info